GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations

Green, Claire L., Tawana, Kiran, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Bodor, Csaba, Fitzgibbon, Jude, Inglott, Sarah, Ancliff, Phil, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2013. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. British Journal of Haematology 161 (5) , pp. 701-705. 10.1111/bjh.12317

Full text not available from this repository.

Abstract

GATA2 mutations have recently been reported in acute myeloid leukaemia (AML) patients with CEBPA-double mutations. To explore their impact on this favourablerisk disease, we determined GATA2 status in 153 sporadic AML patients and three members of a germ-line CEBPA-mutant family at AML presentation. Overall, 27% (15/55) CEBPA-double, 16% (7/43) CEBPA-single and 0% (0/55) normal karyotype/ CEBPA-wild-type patients were GATA2-mutant. All familial AML patients acquired both a second CEBPA and a GATA2 mutation. CEBPA and GATA2 mutant levels indicated that both mutations were likely to be early events in leukaemogenesis. GATA2 status did not impact on the favourable outcome of CEBPAdouble/ FLT3-inernal tandem duplication-negative patients.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49811

Citation Data

Cited 44 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item